Glenmark Pharmaceuticals board meeting scheduled for May 29, 2026 to approve audited financial results for Q4 and FY ending March 31, 2026.
Board will consider recommending dividend for FY2026 on equity shares during the meeting.
Trading window closed from March 31 to May 31, 2026 for directors and designated persons ahead of results announcement.